The Development of Pancreatic Injury in the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
NCT ID: NCT04433754
Last Updated: 2020-06-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2020-03-01
2020-06-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, it was aimed retrospective analysis of clinical and laboratory data of patients who developed pancreatic injury in the course of COVID 19 disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lipase Levels and Coronavirus Disease 2019
NCT05601258
The Commonest Medical, Surgical, and Oncological Causes of Acute Abdomen in Adults With COVID-19. A Prospective Observational Study.
NCT05295251
Evaluation of Prognosis and Prognostic Scores in Geriatric Patients With Acute Pancreatitis
NCT02223325
Identification of the Impact of Acute Pancreatitis on Quality of Life
NCT04222075
A Prospective Study of Natural History of Pancreatitis
NCT00685087
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with pancreatic injury
patients with higher amylase and lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
biochemical analysis
cRP, d-dimer levels and lymphocyte counts will be compared
patients without pancreatic injury
patients with normal amylase and lipase levels in the course of SARS-CoV-2 infection
biochemical analysis
cRP, d-dimer levels and lymphocyte counts will be compared
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biochemical analysis
cRP, d-dimer levels and lymphocyte counts will be compared
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients whose amylase and lipase levels were not measured during covid 19 disease
* Patients with known solid organ malignacy
* Patients with known hematologic malignacy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Uşak University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cevdet Duran
Professor, M.D.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Usak University Training and Research Hospital
Uşak, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UsakU-Cevdet2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.